Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

Abstract

BACKGROUND:

In several cross-sectional analyses, circulating baseline levels of galectin-3, a protein involved in myocardial fibrosis and remodeling, have been associated with increased risk for morbidity and mortality in patients with heart failure (HF). The importance and clinical use of repeated measurements of galectin-3 have not yet been reported.

METHODS AND RESULTS:

Plasma galectin-3 was measured at baseline and at 3 months in patients enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial (n=1329), and at baseline and at 6 months in patients enrolled in the Coordinating Study Evaluating Outcomes of Advising and Counseling Failure (COACH) trial (n=324). Patient results were analyzed by categorical and percentage changes in galectin-3 level. A threshold value of 17.8 ng/mL or 15% change from baseline was used to categorize patients. Increasing galectin-3 levels over time, from a low to high galectin-3 category, were associated with significantly more HF hospitalization and mortality compared with stable or decreasing galectin-3 levels (hazard ratio in CORONA, 1.60; 95% confidence interval, 1.13-2.25; P=0.007; hazard ratio in COACH, 2.38; 95% confidence interval, 1.02-5.55; P=0.046). In addition, patients whose galectin-3 increased by >15% between measurements had a 50% higher relative hazard of adverse event than those whose galectin-3 stayed within ±15% of the baseline value, independent of age, sex, diabetes mellitus, left ventricular ejection fraction, renal function, medication (β-blocker, angiotensin converting enzyme inhibitor, and angiotensin receptor blocker), and N-terminal probrain natriuretic peptide (hazard ratio in CORONA, 1.50; 95% confidence interval, 1.17-1.92; P=0.001). The impact of changing galectin-3 levels on other secondary end points was comparable.

CONCLUSIONS:

In 2 large cohorts of patients with chronic and acute decompensated HF, repeated measurements of galectin-3 level provided important and significant prognostic value in identifying patients with HF at elevated risk for subsequent HF morbidity and mortality.

• Authors: A Rogier van der Velde, Lars Gullestad, Thor Ueland, Pål Aukrust, Yu Guo, Aram Adourian, Pieter Muntendam, Dirk J van Veldhuisen, Rudolf A de Boer
• Journal: Circulation. Heart failure (Circ Heart Fail) Vol. 6 Issue 2 Pg. 219-26 (Mar 2013) ISSN: 1941-3297 [Electronic] United States
• PMID: 23395934 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers
• Galectin 3

Topics

• Acute Disease
• Aged
• Aged, 80 and over
• Biomarkers (blood)
• Chi-Square Distribution
• Chronic Disease
• Female
• Galectin 3 (blood)
• Heart Failure (blood, mortality, therapy)
• Hospitalization
• Humans
• Male
• Middle Aged
• Multivariate Analysis
• Prognosis
• Proportional Hazards Models
• Risk Assessment
• Risk Factors
• Time Factors
• Up-Regulation